South & Central America Custom Antibody Services Market
No. of Pages: 156 | Report Code: BMIRE00032165 | Category: Life Sciences
No. of Pages: 156 | Report Code: BMIRE00032165 | Category: Life Sciences
The South & Central America custom antibody services market size is expected to reach US$ 49.87 million by 2031 from US$ 23.73 million in 2023. The market is estimated to record a CAGR of 9.7% from 2023 to 2031.
The custom antibody services market in South & Central America is gradually expanding, driven by growing investment in biomedical research, increasing prevalence of chronic diseases, and a rising demand for targeted therapeutics. Countries like Brazil and Argentina are emerging as key contributors due to improvements in research infrastructure and healthcare spending. Academic institutions and biotechnology firms in the region are increasingly outsourcing antibody development to specialized service providers to accelerate drug discovery and diagnostics. Although the market faces challenges such as limited funding and regulatory hurdles, technological advancements and international collaborations are expected to support steady growth in the coming year.
Key segments that contributed to the derivation of the South & Central America custom antibody services market analysis are product type, service type, application, disease indication, source, and end user.
Recombinant antibody engineering has a wide scope of potential for drug developers and researchers to create specific molecules with specific attributes ideally suited for treating specific diseases. Several drug developers are already using AI technologies in the prediction and analysis of potential therapeutics from antibody sequences, using algorithms to assess their potential before production has commenced. For instance, Foundation Medicine develops, manufactures, and sells genomic profiling assays on the basis of next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas that can be utilized to match patients with targeted therapies, immunotherapies, and clinical trial options. Such companies also partner with the biopharma industry to help discover, develop, and distribute the next breakthrough treatments for patients. The Medicines Discovery Catapult is testing (on a computer) an in-silico pipeline for identifying new molecules for cancer treatment; for example, applying AI to find new disease drivers as well as candidate drugs for lung cancer. Thus, technological advancements using recombinant antibodies are expected to bring new trends into the custom antibody services market in the coming years.
Based on country, the South & Central America custom antibody services market comprises Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2023.
The prevalence of chronic diseases has been linked to the aging population in Brazil. According to the Pan American Health Organization in 2022, the country has more than 30 million older adults aged 60 years and above, representing 13% of its population. By 2030, the number of people from this age group will reach nearly 50 million, accounting for 24% of the total population. The World Health Organization (WHO) and the Brazilian Institute of Geography and Statistics reported that the geriatric population in Brazil (aged ≥ 60 years) is expected to reach ~55 million by 2040. Geriatric populations often experience a higher incidence of chronic diseases such as autoimmune disorders, cancer, and infectious diseases. Custom antibodies can be developed to target specific biomarkers associated with these conditions, facilitating more effective diagnosis and treatment.
In October 2020, the Brazilian Health Regulatory Agency authorized Sorrento Therapeutics, a clinical-stage, antibody-centric biopharmaceutical company, to conduct a large-scale Phase 2 Clinical Trial for monoclonal antibodies in mild, moderate, and severe COVID-19 Patients. Further, in December 2020, GenScript received approval from ANVISA to use the cPass SARS-CoV-2 Neutralization Antibody Detection Kit to detect neutralizing antibodies. In April 2021, Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) and PlantPraxis Biotecnologia collaborated to develop a biosimilar pembrolizumab in the Brazilian market. Such government initiatives are expected to encourage more research in the Brazilian biotechnology and biopharmaceutical industries, eventually stimulating the economy and gathering industry interest. Ongoing healthcare infrastructure developments and increasing modern diagnostic laboratories are also projected to fuel the market in the coming years. The Collegiate Board Resolution guides good practice in using antibodies for research and clinical use in Brazil.
Some of the key players operating in the market include Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc. among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The South & Central America Custom Antibody Services Market is valued at US$ 23.73 Million in 2023, it is projected to reach US$ 49.87 Million by 2031.
As per our report South & Central America Custom Antibody Services Market, the market size is valued at US$ 23.73 Million in 2023, projecting it to reach US$ 49.87 Million by 2031. This translates to a CAGR of approximately 9.7% during the forecast period.
The South & Central America Custom Antibody Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Custom Antibody Services Market report:
The South & Central America Custom Antibody Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Custom Antibody Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Custom Antibody Services Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Custom Antibody Services Market
